UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000047187
Receipt number R000053825
Scientific Title Clinical research on [-2] proPSA measurement in a diagnosis of prostate cancer: prostate health index trial. Side study: head to head comparison between [-2] proPSA-related indices and MRI
Date of disclosure of the study information 2022/03/16
Last modified on 2022/03/30 12:17:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical research on [-2] proPSA measurement in a diagnosis of prostate cancer: prostate health index trial.
Side study: head to head comparison between [-2] proPSA-related indices and MRI

Acronym

Importance of [-2] proPSA measurement in a diagnosis of PROstate cancer: Prostate HEalth index Trial. Side study: head to head comparison between [-2] proPSA-related indices and MRI (PROPHET-MRI).

Scientific Title

Clinical research on [-2] proPSA measurement in a diagnosis of prostate cancer: prostate health index trial.
Side study: head to head comparison between [-2] proPSA-related indices and MRI

Scientific Title:Acronym

Importance of [-2] proPSA measurement in a diagnosis of PROstate cancer: Prostate HEalth index Trial. Side study: head to head comparison between [-2] proPSA-related indices and MRI (PROPHET-MRI).

Region

Japan


Condition

Condition

prostate cancer

Classification by specialty

Urology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The comparison of diagnostic accuracy between [-2]proPSA-related indices and PI-RADS, which was evaluated by MRI before prostate biopsy, by using the registered data in PROPHET.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Comparison of diagnostic accuracy (area under ROC curve, sensitivity, specificity, positive predictive value, negative predictive value) between [-2] proPSA-related indices and MRI.

Key secondary outcomes

1) Risk for missing clinical significant prostate cancer in MRI-negative cases, and supplemental performance of [-2] proPSA-related indices.
2) Risk for missing clinical significant prostate cancer in cases under cutoff values of [-2] proPSA-related indices, and supplemental performance of MRI.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit

79 years-old >=

Gender

Male

Key inclusion criteria

1) Patients enrolled in PROPHET
2) Patients who underwent MRI before prostate biopsy

Key exclusion criteria

1) Patients who are intent to withdraw from the study until the date of predefined deadline

Target sample size

109


Research contact person

Name of lead principal investigator

1st name Kazuhiro
Middle name
Last name Suzuki

Organization

Gunma University Graduate School of Medicine

Division name

Department of Urology

Zip code

3718511

Address

3-39-22, Showa-machi, Maebashi-city, Gunma 371-8511, Japan

TEL

027-220-8301

Email

kazu@gunma-u.ac.jp


Public contact

Name of contact person

1st name Kazuro
Middle name
Last name Ito

Organization

Kurosawa Hospital

Division name

Department of Urology

Zip code

370-1203

Address

187, Yanaka-machi, Takasaki, Gunma

TEL

027-352-1166

Homepage URL


Email

kzito@gunma-u.ac.jp


Sponsor or person

Institute

Department of Urology, Gunma University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Institute for Preventive Medicine, Kurosawa Hospital

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Dokkyo Medical University Saitama Medical Center
Japan Community Health care Organization Tokyo Shinjuku Medical Center
Yokohama City University, Graduate School of Medicine
Kagawa University, Faculty of Medicine
Kyushu University Hospital
Nagasaki University Graduate School of Biomedical Science

Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Ethics Committee of Gunma University Hospital

Address

3-39-22, Showa-machi, Maebashi-city, Gunma 371-8511, Japan

Tel

027-220-7111

Email

eguchi@jimu.gunma-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 03 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

109

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2022 Year 01 Month 26 Day

Date of IRB

2022 Year 01 Month 27 Day

Anticipated trial start date

2022 Year 03 Month 01 Day

Last follow-up date

2023 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This additional study is expected to decrease the numbers of unnecessary prostate biopsy by comparing diagnostic accuracy between MRI and [-2]proPSA-related indices.


Management information

Registered date

2022 Year 03 Month 16 Day

Last modified on

2022 Year 03 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000053825